Keyword: NHS

New ads from Britain's pharma trade group talk up the country's process for pricing new drugs—and pharma's role within it.

The path for Ionis’ Tegsedi in the U.K. looked rocky after a preliminary “no” last year from NICE. Fortunately for the drugmaker, that decision was reversed.

Alnylam and Ionis have until just after the start of the new year to appeal NICE's conclusion that their new ATTR drugs are not cost-effective.

In a new five-year deal with the National Health Service, pharma will limit its sales growth on branded drugs to 2% each year.

England's National Health Service, like the pharma industry, is having to make contingency plans for avoiding drug shortages in the face of Brexit.

With stellar vaccine sales for GlaxoSmithKline and Bexsero, GSK is building a $175 million plant in Germany to expand production of the meningococcal B shot.

Health authorities in the U.K. said CAR-T therapies could cost $649,000 to treat acute lymphoblastic leukemia in children.

Pfizer wasted little time in appealing the record £85 million fine imposed by a U.K. cost watchdog for a supply scheme that resulted in a 2,600% price increase on an epilepsy drug sold to the National Health System.